Literature DB >> 24649209

Rituximab used in three cases with relapsed non-Hodgkin's lymphoma.

Murat Elli1, Sema Yilmaz1, Ramazan Aydin2, Sadriye Murat3, Meltem Ceyhan Bilgici2, Ayhan Dagdemir1.   

Abstract

Relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) patients have a poor prognosis. New treatment modalities have been used to improve survival rates in children with relapsed or refractory B-NHL. CD20 is expressed in >98% of childhood B-NHL and a chimeric anti-CD20 monoclonal antibody, rituximab, is increasingly being used at relapse. The aim of the present study was to determine the efficacy of rituximab on relapsed B-NHL. Three B-NHL cases were treated successfully with a combination of intensive chemotherapy protocol plus rituximab.

Entities:  

Keywords:  children; non-Hodgkin’s lymphoma; relapse; rituximab

Year:  2013        PMID： 24649209      PMCID： PMC3915537          DOI： 10.3892/mco.2013.88

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN： 2049-9450


  19 in total

1.  CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience.

Authors:  Ernest Bilić; Ranka Femenić; Josip Konja; Marija Simat; Klara Dubravcić; Drago Batinić; Suncica Ries; Ljubica Rajić
Journal:  Coll Antropol       Date:  2010-03

2.  Rituximab in a child with relapsed Burkitt lymphoma.

Authors:  Ali Bay; Murat Dogan; Mehmet Acikgoz; Ahmet Faik Oner
Journal:  Pediatr Blood Cancer       Date:  2007-08       Impact factor: 3.167

3.  Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation.

Authors:  Selim Corbacioglu; Stefan Eber; Tayfun Gungor; Jorg Hummerjohann; Felix Niggli
Journal:  J Pediatr Hematol Oncol       Date:  2003-04       Impact factor: 1.289

4.  Use of rituximab in three children with relapsed/refractory Burkitt lymphoma.

Authors:  Sinan Akbayram; Murat Doğan; Cihangir Akgün; Fatih Erbey; Hüseyin Caksen; Ahmet Faik Oner
Journal:  Target Oncol       Date:  2010-09-22       Impact factor: 4.493

5.  Ongoing development of monoclonal antibodies and antibody drug-conjugates in lymphoma.

Authors:  Eileen M Boyle; Franck Morschhauser
Journal:  Curr Oncol Rep       Date:  2011-10       Impact factor: 5.075

Review 6.  Primary central nervous system lymphoma in children.

Authors:  Oussama Abla; Sheila Weitzman
Journal:  Neurosurg Focus       Date:  2006-11-15       Impact factor: 4.047

7.  Treatment of childhood autoimmune haemolytic anaemia with rituximab.

Authors:  P Quartier; B Brethon; P Philippet; J Landman-Parker; F Le Deist; A Fischer
Journal:  Lancet       Date:  2001-11-03       Impact factor: 79.321

8.  A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Timothy C Griffin; Sheila Weitzman; Howard Weinstein; Myron Chang; Mitchell Cairo; Robert Hutchison; Bruce Shiramizu; Joseph Wiley; Deborah Woods; Margaret Barnich; Thomas G Gross
Journal:  Pediatr Blood Cancer       Date:  2009-02       Impact factor: 3.167

9.  Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group.

Authors:  Andishe Attarbaschi; Michael Dworzak; Manuel Steiner; Christian Urban; Franz-Martin Fink; Alfred Reiter; Helmut Gadner; Georg Mann
Journal:  Pediatr Blood Cancer       Date:  2005-01       Impact factor: 3.167

Review 10.  Use of rituximab, the new FDA-approved antibody.

Authors:  G A Leget; M S Czuczman
Journal:  Curr Opin Oncol       Date:  1998-11       Impact factor: 3.645
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.